Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Autor: Mikol, Dd1, Barkhof, F, Chang, P, Coyle, Pk, Jeffery, Dr, Schwid, Sr, Stubinski, B, Uitdehaag, B, Ballario, Ch, Caceres, Fj, Correale, J, Cristiano, E, Garcea, Do, Leutic, Gg, Aicher, F, Barreira, Aa, Freedman, M, Grand'Maison, F, Jacques, F, Lee, L, Stefanelli, M, Edan, G, Pelletier, J, Berghoff, M, Keifer, R, Koehler, J, Hardiman, O, Comi, G, Mancardi, GIOVANNI LUIGI, Pozzilli, C, Trojano, Mp, Jongen, P, Uitdehaag, Bm, Belova, An, Boyko, An, Elchaninov, Ap, Kozlov, Va, Odinak, Mm, Shvarkov, Sb, Skoromets, Aa, Spirin, Nn, Stolyarov, Id, Vorobieva, Ov, Zavalishin, I, Arbizu, T, Fernandez, O, Izquierdo, G, Montalban, X, Goebels, N, Bates, D, Constantinescu, C, Turner, B, Bashir, K, Bever, Ct, Birnbaum, G, Brod, Sa, Carlini, W, Dunne, P, Elias, S, Estronza, N, Fox, E, Glyman, S, Gross, J, Guarnaccia, Jb, Gupta, A, Kaufman, M, Khan, O, Khatri, B, Kresa reahl, K, Lava, N, Leist, T, Markowitz, C, Mihai, C, Mikol, Dd, Miller, T, Panitch, H, Parry, G, Rammohan, Kw, Reder, A, Sheppard, C, Simsarian, Jp, Smiroldo, J, Spier, L, Thrower, B, Vollmer, T, Wendt, J, Wray, S, Wynn, D.

Publikováno v: Mikol, D D, Barkhof, F, Chang, P, Coyle, P K, Jeffery, D R, Schwid, S R, Stubinski, B & Uitdehaag, B M J 2008, ' Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial ', Lancet Neurology, vol. 7, no. 10, pp. 903-914 . https://doi.org/10.1016/S1474-4422(08)70200-X
Lancet Neurology, 7(10), 903-914. Lancet Publishing Group

Summary Background Interferon beta-1a and glatiramer acetate are commonly prescribed for relapsing-remitting multiple sclerosis (RRMS), but no published randomised trials have directly compared these two drugs. Our aim in the REGARD (REbif vs Glatira

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf18e8a5ef741d37534d0198c937a14
https://doi.org/10.1016/s1474-4422(08)70200-x

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Autor: MIKOL DD, BARKHOF F, CHANG P, COYLE PK, JEFFERY DR, SCHWID SR, STUBINSKI B, UTIDEHAAG BM, COMI , GIANCARLO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10495::8398046553a85d8772be2fd41053daa3

NEUROLOGIC COMPLICATIONS OF LYME DISEASE

Autor: Coyle Pk

Publikováno v: Rheumatic Disease Clinics of North America. 19:993-1009

Lyme disease is now the most frequent vector-borne infection in the United States. It is due to a spirochete, Borrelia burgdorferi, which is inoculated into the host by the bite of an infected Ixodes (hard body) tick. The nervous system is frequently

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a10cceb2ded11e78cd8af3bdfbdff41
https://doi.org/10.1016/s0889-857x(21)00217-9

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.